(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 December 2010 (29.12.2010)

PCT

(10) International Publication Number
WO 2010/151823 A1

(51) International Patent Classification:
G01N 33/48 (2006.01) *A61K 38/00* (2006.01)

(21) International Application Number:
PCT/US2010/040082

(22) International Filing Date:
25 June 2010 (25.06.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/269,669	25 June 2009 (25.06.2009)	US
61/248,698	5 October 2009 (05.10.2009)	US
61/298,718	27 January 2010 (27.01.2010)	US

(71) Applicant *(for all designated States except US)*: **SAVIENT PHARMACEUTICALS INC.** [US/US]; One Tower Center Boulevard, East, Brunswick, NJ 08816 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ROSARIO-JANSEN, Theresa** [US/US]; 12 Laurel Hill Drive, Randolph, NJ 07869 (US). **WRIGHT, David, Erick** [US/US]; 17140 Woodson View Lane, Romona, CA 92065 (US).

(74) Agents: **ACHKAR, Charles** et al.; Kramer Levin Naftalis & Frankel LLP, 1177 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2010/151823 A1

(54) Title: METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY

(57) Abstract: Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.